IL6 and COVID-19: Although overproduction of IL-6 mediates the low HLA-DR expression on CD14+ monocytes of patients with severe COVID-19 (Giamarellos-Bourboulis et al., 2020; Silvin et al., 2020), anti-IL6 therapy has been unsuccessful in showing improved outcomes in COVID-19 (Stone et al., 2020), highlighting the urgent need for elucidating the underlying mechanisms.